{"id":2449,"date":"2018-03-12T16:03:37","date_gmt":"2018-03-12T16:03:37","guid":{"rendered":"http:\/\/cardiologynownews.org\/?p=2449"},"modified":"2018-04-09T14:48:06","modified_gmt":"2018-04-09T14:48:06","slug":"andexanet-alfa-rapid-reversal-of-factor-xa-inhibitors","status":"publish","type":"post","link":"https:\/\/cardiologynownews.org\/?p=2449","title":{"rendered":"Andexanet alfa: Rapid reversal of Factor Xa inhibitors"},"content":{"rendered":"<p>On Monday, March 12<sup>th<\/sup> at ACC 2018 in Orlando, Florida, an interim analysis from the ongoing ANNEXA-4 study demonstrated that the first- in-class reversal drug for direct and indirect factor Xa inhibitors, Andexanet alfa, was able to effectively reverse the anti-factor Xa activity and control major bleeding events among patients taking one of four Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban or enoxaparin).<!--more--><\/p>\n<p>Stuart Connolly, MD reported the occurrence of the two primary efficacy endpoints: % of patients with bleeding control within 12 hours following the administration of andexanet alfa \u00a0and reduction in Anti-Factor Xa inhibitor activity. The safety endpoint were the rates of 30-day mortality and thrombotic events. This prospective, multicenter single arm cohort of 227 patients with active major bleeding \u00a0within 18 hours of taking a Factor Xa demonstrated the efficacy of andexanet alfa to stop the bleeding events : 83% of the patients at 12 hours (CI = 0.75-0.89). Moreover, there was a 88% median reduction in anti-factor Xa inhibitor activity among patients taking rivaroxaban, 91% with apixaban and 75% with enoxaparin.<\/p>\n<p>[perfectpullquote align=&#8221;full&#8221; bordertop=&#8221;false&#8221; cite=&#8221;&#8221; link=&#8221;&#8221; color=&#8221;&#8221; class=&#8221;&#8221; size=&#8221;&#8221;]The 30-day mortality was 12% and the rate of thrombotic events was 2.6% and 11% at 3 days and 30 days respectively.[\/perfectpullquote]<\/p>\n<p>After the first preliminary report of the ANNEXA study published in the <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1607887\" target=\"_blank\" rel=\"noopener\"><em>NEJM<\/em><\/a>, this new analysis suggest \u00a0both safety and efficacy of Andexanet alfa to reverse the effect of Factor Xa inhibitor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On Monday, March 12th at ACC 2018 in Orlando, Florida, an interim analysis from the ongoing ANNEXA-4 study demonstrated that the first- in-class reversal drug for direct and indirect factor Xa inhibitors, Andexanet alfa, was able to effectively reverse the anti-factor Xa activity and control major bleeding events among patients taking one of four Factor [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[160,29,8],"tags":[],"ppma_author":[1047],"class_list":{"0":"post-2449","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-acc-2018","7":"category-conferences","8":"category-news","9":"author-mkhurramafzal"},"authors":[{"term_id":1047,"user_id":32,"is_guest":0,"slug":"mkhurramafzal","display_name":"M. Khurram Afzal, M.D.","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/e862b49d9bb577f0e9babf17e98a2a43fa27626d672894af66eb036ccd3af84e?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/2449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2449"}],"version-history":[{"count":12,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/2449\/revisions"}],"predecessor-version":[{"id":2824,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/2449\/revisions\/2824"}],"wp:attachment":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2449"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fppma_author&post=2449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}